Regencell Bioscience Holdings Limited Stock
Equities
RGC
KYG7487R1002
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4 USD | -2.20% |
|
-16.14% | -61.90% |
Sales 2022 | - | Sales 2023 | - | Capitalization | 300M 411M |
---|---|---|---|---|---|
Net income 2022 | -7M -9.59M | Net income 2023 | -5M -6.85M | EV / Sales 2022 | - |
Net cash position 2022 | 15.65M 21.43M | Net cash position 2023 | 11.1M 15.2M | EV / Sales 2023 | - |
P/E ratio 2022 |
-59.5
x | P/E ratio 2023 |
-51.1
x | Employees | 12 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 11.24% |
1 day | -2.20% | ||
1 week | -16.14% | ||
Current month | -14.89% | ||
1 month | -26.74% | ||
3 months | +14.29% | ||
6 months | -58.93% | ||
Current year | -61.90% |
![Extreme 4.0001](/images/extremecours_fleche.png)
![Extreme 4.0001](/images/extremecours_fleche.png)
![Extreme 3.16](/images/extremecours_fleche.png)
![Extreme 3.16](/images/extremecours_fleche.png)
![Extreme 3.16](/images/extremecours_fleche.png)
![Extreme 3.16](/images/extremecours_fleche.png)
![Extreme 3.16](/images/extremecours_fleche.png)
Managers | Title | Age | Since |
---|---|---|---|
Wai Hong Chung
COO | Chief Operating Officer | 46 | - |
Yi-Chung Chao
CTO | Chief Tech/Sci/R&D Officer | 59 | 20-09-30 |
Yat-Pui Au
PRN | Corporate Officer/Principal | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Wing Yan Lo
BRD | Director/Board Member | 63 | 21-12-12 |
Yi-Chung Chao
CTO | Chief Tech/Sci/R&D Officer | 59 | 20-09-30 |
- | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-20 | 4 | -2.20% | 304 |
24-06-18 | 4.09 | +0.24% | 560 |
Delayed Quote Nasdaq, June 20, 2024 at 04:30 pm
More quotes1st Jan change | Capi. | |
---|---|---|
-61.90% | 52.05M | |
+34.14% | 51.12B | |
-6.54% | 39.4B | |
+34.92% | 38.48B | |
+12.62% | 26.36B | |
-12.11% | 26.22B | |
-13.43% | 20.96B | |
+43.73% | 14.02B | |
+31.81% | 12.49B | |
-4.54% | 11.61B |
- Stock Market
- Equities
- RGC Stock